ArticleCureus2025
Efficacy and Safety of Polyherbal Formulation in Low Sperm Count Participants: A Randomized, Multicenter, Double-Blinded, Placebo-Controlled, Interventional Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMale infertility, particularly oligospermia, is characterized by reduced sperm count. It remains a significant clinical concern due to its multifactorial origin and limited therapeutic options. The present study investigates the efficacy and safety of "SHL 1066," a standardized polyherbal formulation, in enhancing semen quality and improving sexual health outcomes in men with low sperm counts. MATERIALS AND
methodsIn a 90-day, multicenter, randomized, double-blinded, placebo-controlled trial, 60 male participants were randomly assigned to receive either "SHL 1066" or a placebo using a computer-generated randomization protocol. Assessments of sperm count, motility, serum total testosterone, and sexual health parameters (erectile function, intercourse satisfaction, and overall satisfaction) were conducted at baseline and study completion.
resultsAfter 90 days, "SHL 1066" significantly increased sperm count by 72.5% and motility by 14.4%, compared to 8.6% and 6.3%, respectively, in the placebo group. Serum total testosterone levels rose by 23.3%. Sexual health outcomes improved markedly, with erectile function enhanced by 45.5%, intercourse satisfaction by 52.8%, and overall satisfaction by 54%, substantially surpassing placebo outcomes.
conclusion"SHL 1066" demonstrated safety, tolerability, and significant efficacy in improving sperm count, motility, testosterone levels, and sexual health compared to placebo. These results position "SHL 1066" as a promising therapeutic option for managing male infertility by enhancing semen quality and sexual function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.